Page last updated: 2024-09-04

docetaxel anhydrous and zibotentan

docetaxel anhydrous has been researched along with zibotentan in 4 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (zibotentan)	Trials (zibotentan)	Recent Studies (post-2010) (zibotentan)
12,110	3,216	6,920	67	18	46

Protein Interaction Comparison

Protein	Taxonomy	docetaxel anhydrous (IC50)	zibotentan (IC50)
Endothelin-1 receptor	Homo sapiens (human)		0.021

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Burris, HA; de Bono, JS; Hubner, A; Miller, K; Morris, T; Nathan, F; Payne, H; Stephenson, J; Taboada, M; Trump, DL	1
Fizazi, K; Fizazi, KS; Gleave, M; Higano, CS; McIntosh, S; Miller, K; Morris, T; Moul, JW; Nathan, FE; Nelson, JB; Pemberton, K	1
Chen, M; He, ZH; Qi, P; Song, RX; Wang, ZP; Zhang, LX	1

Reviews

1 review(s) available for docetaxel anhydrous and zibotentan

Article	Year
A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer. PloS one, 2015, Volume: 10, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease-Free Survival; Docetaxel; Endothelin A Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2015

Article

Year

A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.

PloS one, 2015, Volume: 10, Issue:7

Topics: Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease-Free Survival; Docetaxel; Endothelin A Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome

2015

Trials

2 trial(s) available for docetaxel anhydrous and zibotentan

Article	Year
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The Prostate, 2011, Volume: 71, Issue:12 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Orchiectomy; Pain; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome	2011
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Failure	2013

Article

Year

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.

The Prostate, 2011, Volume: 71, Issue:12

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Orchiectomy; Pain; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome

2011

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Failure

2013

Other Studies

1 other study(ies) available for docetaxel anhydrous and zibotentan

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013